Roth Capital Partners served as the exclusive placement agent for a $4.5 million registered direct offering completed by Biofrontera, a biopharmaceutical company specializing in the commercialization of dermatologic products. Biofrontera entered into a securities purchase agreement pursuant to which Biofrontera agreed to issue and sell an aggregate of 150,000 shares of common stock, pre-funded warrants to purchase 1,055,000 shares of common stock and warrants to purchase 1,807,500 shares of common stock.
Faegre Drinker served as legal counsel for Roth Capital Partners in the transaction.
